8-K: Beta Bionics Reports Strong Preliminary Q4 2025 Results

Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results showing significant growth in net sales and customer base.

Summary

• Net sales are expected to be at least $32.0 million for Q4 2025, representing an increase of at least 56% compared to $20.4 million in Q4 2024.
• Durable Medical Equipment (DME) channel net sales are projected to be at least $22.3 million, up at least 23% from $18.1 million in Q4 2024.
• Pharmacy Benefit Plan (PBP) channel net sales are expected to reach at least $9.7 million, a substantial increase of at least 308% from $2.4 million in Q4 2024.
• The installed customer base is anticipated to be at least 35,000 users, marking an increase of at least 128% from 15,298 in Q4 2024.
• New patient starts are expected to be at least 5,581, an increase of at least 36% compared to 4,084 new patient starts in Q4 2024.
• Approximately 69% of new patient starts are expected to have transitioned from multiple daily injections (MDI).
• A low-30s percentage of new patient starts are expected to be reimbursed through the PBP channel, showing an increase relative to the prior quarter.
• Approximately 25-30% of new patient starts are expected to be people with type 2 diabetes, also increasing relative to the prior quarter.

Sentiment

Score: 8

Explanation: The preliminary results show very strong growth across key financial and operational metrics, including net sales, customer base, and new patient starts, particularly in the PBP channel. While preliminary and unaudited, the magnitude of growth is highly positive.

Positives

• Significant growth in overall net sales, up at least 56% year-over-year.
• Exceptional growth in the Pharmacy Benefit Plan (PBP) channel net sales, increasing by at least 308%.
• Strong expansion of the installed customer base, growing by at least 128%.
• Solid increase in new patient starts, up at least 36%.
• High percentage (approximately 69%) of new patient starts coming from multiple daily injections (MDI), indicating successful conversion from traditional methods.
• Increasing penetration into the PBP channel and the type 2 diabetes patient segment, suggesting broader market acceptance and access.

Risks

• The preliminary, unaudited financial information is subject to adjustment and may differ materially from the final audited financial statements.
• Inherent risks associated with developing product candidates in the medical device industry.
• Uncertainty regarding future results from ongoing and future studies and clinical trials.
• The company's ability to obtain adequate financing to fund product development and other expenses.
• Real-world data or future results may not be consistent with interim, initial, or preliminary results or results from prior preclinical studies or clinical trials.
• Exposure to trends in the industry and potential impacts of global macroeconomic conditions.
• Reliance on relationships with existing and future collaboration partners.
• Challenges related to the legal and regulatory framework for the industry.
• Uncertainty regarding future expenditures.

Future Outlook

The company expects to continue its growth trajectory, particularly in the Pharmacy Benefit Plan channel and among type 2 diabetes patients. Management plans to host in-person meetings with investors to discuss these preliminary results and will report full fourth quarter and full year 2025 financial results on February 17, 2026.

Management Comments

• Management will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics.
• The company plans to report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026 after the close of market, followed by a conference call and concurrent webcast.

Industry Context

Beta Bionics operates in the rapidly evolving diabetes management market, which is seeing increasing demand for advanced, automated insulin delivery systems like the iLet Bionic Pancreas. The significant growth in its PBP channel and increasing adoption by type 2 diabetes patients suggest successful market penetration and alignment with broader industry trends towards integrated and accessible diabetes care solutions. The high conversion rate from multiple daily injections (MDI) indicates the iLet system's appeal as an improved alternative to traditional methods.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards.
• However, the reported growth rates of at least 56% in net sales and at least 128% in installed customer base are indicative of strong performance within the medical device and diabetes technology sector, which often sees high growth for innovative, FDA-cleared solutions.
• The increasing penetration into the PBP channel and the type 2 diabetes market segment suggests the company is effectively expanding its market reach, a key indicator of success in the competitive diabetes care landscape.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong growth in sales and customer base, potentially leading to increased share value.
• Customers (people with diabetes): Continued expansion and adoption of the iLet Bionic Pancreas suggests improved access to advanced diabetes management solutions.
• Employees: Positive outlook due to company growth and market expansion, potentially leading to job stability and opportunities.
• Creditors/Suppliers: Strong financial performance could enhance the company's creditworthiness and strengthen relationships.

Next Steps

• Members of management will host in-person meetings in San Francisco, CA from January 12-14, 2026, to discuss the preliminary results.
• The company plans to report its full fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, after market close.
• A conference call and concurrent webcast will be hosted on February 17, 2026, at 4:30 pm Eastern Time to review performance.

Key Dates

Recommendation

The preliminary Q4 2025 results indicate exceptional growth across all key metrics, including a 56% increase in net sales and a 128% expansion of the installed customer base. The substantial 308% growth in the PBP channel and increasing penetration into the type 2 diabetes market demonstrate strong market acceptance and effective commercialization of the iLet Bionic Pancreas. While these results are unaudited, the magnitude of the reported growth suggests significant positive momentum and strong underlying business performance, making Beta Bionics an attractive investment opportunity.

Keywords

diabetes management, iLet Bionic Pancreas, medical device, insulin delivery, closed-loop algorithm, financial results, net sales, customer base, patient starts, DME, PBP, type 2 diabetes